Last reviewed · How we verify

NCT05702489

A Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults with Uncomplicated Influenza

Completed Phase 2, PHASE3 Last updated 5 November 2024
What this trial tests

Phase 2, PHASE3 trial testing ZX-7101A in Influenza, Human in 900 participants. Completed in 13 October 2023.

Timeline
17 July 2022
Primary endpoint
26 May 2023
13 October 2023

Quick facts

Lead sponsorNanjing Zenshine Pharmaceuticals
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment900
Start date17 July 2022
Primary completion26 May 2023
Estimated completion13 October 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Nanjing Zenshine Pharmaceuticals — full company profile →

Who can join

Adults 18 to 64, any sex, with Influenza, Human. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare ZX-7101A in Chinese Adults patients with uncomplicated influenza. The main questions it aims to answer are: * The efficacy of ZX-7101A in Chinese Adults patients with uncomplicated influenza. * The safety of ZX-7101A in Chinese Adults patients with uncomplicated influenza.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ZX-7101A

Trials testing the same drug.

Other recruiting trials for Influenza, Human

Currently open trials in the same condition.

Other Nanjing Zenshine Pharmaceuticals trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05702489.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing